Vicapsys Life Sciences, Inc. (VICP)
OTCMKTS · Delayed Price · Currency is USD
1.770
+0.500 (39.37%)
At close: Mar 24, 2025
Vicapsys Life Sciences Company Description
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product.
The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field.
It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers.
The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017.
Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
Vicapsys Life Sciences, Inc.
| Country | United States |
| Founded | 1997 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Federico Pier |
Contact Details
Address: 7778 Mcginnis Ferry Road Suwanee, Florida 30024 United States | |
| Phone | 972 891 8033 |
| Website | vicapsys.com |
Stock Details
| Ticker Symbol | VICP |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US92560A1060 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Federico Pier | Chief Executive Officer, Executive Chairman and Interim President |
| Jeffery Wright CPA, CPA | Chief Financial Officer |
| Dr. Mark C. Poznansky M.D., Ph.D. | Chief Scientist Advisor and Founder |